# US 2013/0157984 A1 · Prostaglandin-bisphosphonate conjugate compounds, methods of making same, and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0157984 A1
- Document ID: US20130157984A1
- Status: Published application
- Kind: A1
- Application number: 13/687,762
- Filed: 2012-11-28
- Published: 2013-06-20
- Earliest claimed: 2010-05-28
- Assignees: Simon Fraser University
- Inventors: Robert N. Young; Stephen Arns; Anne Moreau; Monzur Morshad; Romelo Gibe
- Web page: https://patentgrep.com/patent/US20130157984A1

## CPC

- C07F 9/572: Five-membered rings
- A61K 47/548: {Phosphates or phosphonates, e.g. bone-seeking (phospholipids A61K47/544)}
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 19/10: for osteoporosis
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07F 9/3873: {containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)}
- C07F 9/59: Hydrogenated pyridine rings
- C07F 9/6512: having the nitrogen atoms in positions 1 and 3
- C07F 9/65583: {each of the hetero rings containing nitrogen as ring hetero atom}
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides in part, conjugate compounds. The invention also provides synthesis methods for making the compounds, and uses of the compounds.

## Claims

### Claim 1

A compound according to Formula I, or a pharmaceutically acceptable salt thereof:
wherein:
X is —C—, —S—, —O—, or —NH—;
R2 and R3 are each independently —H or halo;
Ar is aryl;
W is —H, —C(O)V, or —C(O)OV;
Y is optionally substituted tetrazole, —C(O)OR1, or —C(O)NHSO2R′;
n is 1, 2 or 3;
V is optionally substituted lower alkyl, optionally substituted aryl, or optionally substituted heteroalkyl;
R1 is H or optionally substituted lower alkyl;
R′ is optionally substituted lower alkyl or optionally substituted aryl; and
is a double or single bond,
and wherein Y or W is conjugated to a bisphosphonate moiety.

### Claim 2 (depends on 1)

The compound of claim 1, wherein the bisphosphonate moiety is conjugated via a linker.

### Claim 3 (depends on 1)

The compound of claim 1, wherein:
R1 is —(CR5R6)—O—C(O)—O—Ar, wherein Ar is optionally substituted aryl, R5 is lower alkyl, and R6 is H or lower alkyl.

### Claim 4 (depends on 1)

The compound of claim 1, wherein:
R1 is —(CR5R6)—O—C(O)—NH—(CH2)m—C(PO3H2)2OH, wherein R5 is lower alkyl; R6 is H or lower alkyl and m is 1, 2, 3, 4, 5, or 6.

### Claim 5 (depends on 1)

The compound of claim 1, wherein:
when W is H, Y is optionally substituted tetrazole and X is CH2.

### Claim 6 (depends on 1)

The compound of claim 1, wherein:
Y is —C(O)OR1;
W is
m is 1, 2, 3, 4, 5, or 6; and
R1 is lower alkyl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein:
Y is —C(O)OR1, tetrazole, or N-trityl-tetrazole;
W is
R7 and R8 are each independently H, small alkyl, cycloalkyl group or CF3;
m is 1, 2, 3, 4, 5, or 6; and
o is 0, 1, 2, 3, 4, 5, or 6.

### Claim 8

A compound according to Formula IV or V, or a pharmaceutically acceptable salt thereof:
wherein:
X is —C—, —S—, —O—, or —NH—;
R1 and R2 are each independently H, small alkyl, cycloalkyl group or CF3;
R3 is a electron donating or electron withdrawing group;
m is 1, 2, or 3;
n is 1, 2, 3, or 4; and
o is 1, 2, 3, or 4.

### Claim 9 (depends on 1)

The compound of claim 1, wherein the compound is hydrolysable in vivo.

### Claim 10 (depends on 9)

The compound of claim 9, wherein the compound is inactive prior to hydrolysis or is active subsequent to hydrolysis.

### Claim 11 (depends on 8)

The compound of claim 8, wherein the compound is hydrolysable in vivo.

### Claim 12 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 in combination with a pharmaceutically acceptable carrier.

### Claim 13 (depends on 8)

A pharmaceutical composition comprising the compound of claim 8, in combination with a pharmaceutically acceptable carrier.

### Claim 14 (depends on 1)

A method of selectively delivering a compound to bone or an associated site, the method comprising administering an effective amount of the compound of claim 1 to a subject in need thereof.

### Claim 15 (depends on 14)

The method of claim 14 wherein the associate site comprises a site adjacent to a bone in need of treatment.

### Claim 16 (depends on 14)

The method of claim 14 wherein the bone in need of treatment is selected from the group consisting of a green stick fracture, compound fracture, lateral fracture, pathologic fracture resulting from an invasive tumor, compression fracture, and fracture requiring a surgical procedure for realignment of a bone.

### Claim 17 (depends on 1)

A method of treating or preventing a condition associated with abnormal or excessive bone loss, or with abnormal or reduced bone resorption, or with abnormal calcium metabolism comprising administering an effective amount of the compound of claim 1 to a subject in need thereof.

### Claim 18 (depends on 17)

The method of claim 17, wherein the condition is selected from the group consisting of osteoporosis, glucocorticoid-induced osteoporosis, Paget's disease, abnormally increased bone turnover, bone graft, periodontal disease, alveolar bone loss, tooth loss, bone fracture, periprostheticosteolysis, osteogenesisimperfecta, and metastatic bone disease.

### Claim 19 (depends on 17)

The method of claim 17 wherein the subject is a human.

### Claim 20 (depends on 1)

A method of making a compound according to claim 1 comprising:
a) providing a EP4 agonist having a C-1 carboxyl group or tetrazoyle moiety
b) providing a bisphosphonate with a free primary or secondary amino moiety; and
c) conjugating the EP4 agonist and the bisphosphonate.
